Navitoclax - Wikipedia
WEBClinical trials. Antisclerotic. References. Navitoclax (previously ABT-263) is an experimental orally active anti- cancer drug, which is a Bcl-2 inhibitor similar in action to obatoclax. [1] [2] Mechanism of action. Navitoclax inhibits not only Bcl-2, but also Bcl-X L …
ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor
WEBMay 1, 2008 · In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 exhibits modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. These data provide the rationale for clinical trials evaluating ABT-263 in small-cell lung cancer and B-cell malignancies.
Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven ...
WEBJul 13, 2021 · Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy. Violetta Ritter, Franziska Krautter, Diana Klein, Verena Jendrossek & Justine Rudner....
Navitoclax (ABT-263) | ≥99%(HPLC) | Selleck | Bcl-2 阻害剤
WEBナビトクラックス (Navitoclax (ABT-263)) は Bcl-xL, Bcl-2 and Bcl-w の強力な阻害剤であり、阻害定数は cell-free assay において Ki ≦ 0.5 nM, 1 nM および 1nM です。 一方、Mcl-1 および A1 に対しては比較的弱い結合力を示します。 臨床第2相試験中. CAS No. 923564-51-6. 文献中Selleckの製品使用例 （347） Gastroenterology,2024S0016-5085 …
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
WEBMay 1, 2008 · ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor | Cancer Research | American Association for Cancer Research. Experimental Therapeutics, Molecular Targets, and Chemical Biology | May 01 2008. ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor. Christin Tse; Alexander R. Shoemaker; Jessica …
Targeting anti-apoptotic pathways eliminates senescent ...
WEBDec 23, 2022 · 5 Citations. 30 Altmetric. Metrics. Abstract. Human melanocytic nevi (moles) result from a brief period of clonal expansion of melanocytes. As a cellular defensive mechanism against...
Addition of Navitoclax to Ongoing Ruxolitinib Therapy for ...
WEBFebruary 18, 2022. Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy.
Clinical Review: Navitoclax as a Pro-Apoptotic and Anti ...
WEBNov 25, 2020 · Introduction. Navitoclax is one of the B-cell lymphoma 2 (BCL-2) family protein inhibitors which has been generated during the clinical development of ABT-737 ( Tse et al., 2008 ). This orally bioavailable drug, which was formerly known as ABT-263, has a similar structure to its predecessor, ABT-737.
ABT-263 induces G1/G0-phase arrest, apoptosis and ...
WEBJul 10, 2017 · ABT-263 (Navitoclax), a novel BH3 mimetic and orally bioavailable Bcl-2 family inhibitor with high affinity for Bcl-xL, Bcl-2 and Bcl-w has entered clinical trials for cancer treatment. But the...
ABT-263 Reduces Hypertrophic Scars by Targeting Apoptosis ...
WEBJan 14, 2021 · ABT-263, as an orally bioavailable BCL-2 family inhibitor, has showed great antitumor characteristics by targeting tumor cell apoptosis. The objective of this study was to explore whether ABT-263 could target apoptosis of overactivated myofibroblasts in hypertrophic scar. Methods: In vivo, we used ABT-263 to treat scars in a rabbit ear scar …
Skip to content